ISPOR Europe 2019

Copenhagen schedule

Monday 4 November 2019

Posters

Display hours Session Code Title Authors
10:30-14:00
PNS: No specific disease
PNS217
How central limit theorem relates to the selection of distributions for probabilistic sensitivity analysis
Hale O, Lee D
10:30-14:00
PNS: No specific disease
PNS260
Inclusion of new strategies in the UK’s Cancer Drug Fund: what was decided in France?
Trancart M, Almond C, Sullivan W
15:30-19:00
PCN: Cancer
PCN226
The cost-effectiveness and relapse-reduction benefit of introducing adjuvant nivolumab for patients with completely with resected melanoma with lymph node involvement or metastatic disease in the UK
Ntais D, Batteson R, Hart R, Hemstock M, Lee D
15:30-19:00
PCN: Cancer
PCN345
A review of differences in decision-making across NICE health technology assessments of nivolumab
Horscroft J, Casson J, Sullivan W, Ntais D, Kiff C, Tyas D
15:30-19:00
PCN: Cancer
PCN346
Mean versus median: what does NICE consider to be the most appropriate statistic for estimating short life expectancy to satisfy end-of-life criteria?
Raad A, Lee D
15:30-19:00
PCN: Cancer
PCN380
A targeted review evaluating uncertainty in single technology appraisal submissions for treatments approved for use since the introduction of the ‘new’ Cancer Drugs Fund
Critchlow S, Lilley C, Gladwell D, Akehurst RL, Palmer S, Trevor N, Adedokun L, Lee JM
15:30-19:00
PCN: Cancer
PCN472
Patient reported health state utilities in cutaneous t-cell lymphoma (CTCL) – an analysis of EQ-5D and Skindex-29 data collected from the Alcanza trial
Podkonjak T, McCarthy G, Cranmer H, Birnie R
15:30-19:00
PCN: Cancer
PCN530
The cost-effectiveness and relapse-reduction benefit of introducing adjuvant nivolumab for patients with completely with resected melanoma with lymph node involvement or metastatic disease in the UK
Ntais D, Batteson R, Hart R, Hemstock M, Lee D

Workshop

Time Code Title Discussion leaders Location
17:00-18:00
W8
Improving efficiency in HTA: the role of open source models and more advanced software choice
Raquel Aguiar-Ibáñez, Gianluca Baio, Dawn Lee, R. Brett McQueen
C1 M1

Tuesday 5 November 2019

Posters

Display hours Session Code Title Authors
10:30-14:00
PDB: Diabetes/Endocrine/Metabolic Disorders
PDB32
Would a cohort-level approach to cost-effectiveness modelling have led to a different decision in an important NICE appraisal for obesity patients?
Metry A, Sullivan W, Kearns B, Bullement A
15:45-19:00
PMU: Multiple Diseases
PMU82
Varying willingness-to-pay based on disease burden: Impact on health technology assessment outcomes of specialist drugs in the Netherlands
Schurer M, Vossen CY, van Keep M, Horscroft J, Moorhouse JA, Chapman AM, Akehurst RL
15:30-19:00
PMU: Multiple Diseases
PMU114
Specialised health technology assessment processes for very rare diseases: past, present and future
Akehurst RL, Moorhouse JA, Jones E, Mason N, Schurer M, Chapman AM, Horscroft J

Wednesday 6 November 2019

Poster

Display hours Session Code Title Authors
09:30-14:00
PIH: Individual’s Health
PIH20
A targeted literature review of the economic burden associated with polycystic ovary syndrome
Rajora P, Goli N, Savner R, Singh A, Bhutani MK

Issue Panel

Time Code Title Moderator Panelists Location
08:30-09:30
IP19
How effective are managed access agreements as a vehicle for earlier reimbursement in the presence of uncertainty? Lessons from the new Cancer Drugs Fund
Ron Akehurst
Jennifer M Lee, Stephen Palmer, Steve Williamson
C1 M0

Podium Presentation

Time Code Title Authors Location
14:15-14:30
RW2
Methodological approaches for incorporating real-world overall survival data into long-term survival estimates: case study of a NICE technology appraisal in extensive-stage small-cell lung cancer
Connor S, Orfanos P, Flahavan E, Patterson K, Lee D
C1 M4

Stand C3-046

Email businessdevelopment@bresmed.com to arrange a meeting